Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hypersomnia in Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04006834
Recruitment Status : Recruiting
First Posted : July 3, 2019
Last Update Posted : September 5, 2019
Sponsor:
Information provided by (Responsible Party):
Dr. Zhang Jihui, Chinese University of Hong Kong

Tracking Information
First Submitted Date February 25, 2019
First Posted Date July 3, 2019
Last Update Posted Date September 5, 2019
Actual Study Start Date July 1, 2019
Estimated Primary Completion Date February 28, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 3, 2019)
  • Hypersomnia [ Time Frame: 1 year ]
    Daytime Sleepiness measured by self rated Epworth Sleepiness Scale
  • Depression severity [ Time Frame: 1 year ]
    Clinician rated score by Structure Interview Guide for the Hamilton Depression Rating Scale - Seasonal Affective Disorder (SIGH-SAD)
Original Primary Outcome Measures
 (submitted: July 2, 2019)
  • Hypersomnia [ Time Frame: 1 year ]
    Daytime Sleepiness measured by self rated ESS
  • Depression severity [ Time Frame: 1 year ]
    Clinician rated score by SIGHADS
Change History Complete list of historical versions of study NCT04006834 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: September 3, 2019)
  • Fatigue [ Time Frame: 1 year ]
    Self rated scale by Multidimensional Fatigue Inventory (MFI)
  • Function as indicated quality of life [ Time Frame: 1 year ]
    Self rated by 12-Item Short FOrm Survey (SF12)
Original Secondary Outcome Measures
 (submitted: July 2, 2019)
  • Fatigue [ Time Frame: 1 year ]
    Self rated scale by MFI
  • Function as indicated quality of life [ Time Frame: 1 year ]
    Self rated by SF12
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Hypersomnia in Major Depressive Disorder
Official Title Hypersomnia in Major Depressive Disorder
Brief Summary

Background: MDD is a common mental disorder with significant morbidities and mortalities. Recent local data suggested that depressive disorders have a prevalence of over 12% in females and nearly 7 % in males in Hong Kong general adult population. Other than insomnia, patients with MDD often complained another sleep symptom - hypersomnia (defined as daytime sleepiness or excessive sleep). Interestingly, when compared to insomnia, there is much far less research on the role of hypersomnia in MDD. However, there are available data suggested that hypersomnia is associated with greater treatment-resistance, more recurrence, and increased suicidality, suggesting a need to investigate this problem in MDD patients.

Objective: To investigate the prevalence and determine characteristics of hypersomnia amongst major depressive disorder.

Design: 2-phase study design Setting: A case-control study Participants: Patients with a history of Major Depressive Disorder from out-patient clinics in New Territories East Cluster.

Main outcome measures: Daytime sleepiness measured by MSLT, actigraphy and self-reported questionnaire (ESS), sleep duration as measured by sleep diary and actigraphy.

Detailed Description

Background

Significance of hypersomnia in depressive illness

Sleep disturbances are observed in up to 90% of depressed patients. Both insomnia, defined clinically as difficulty initiating and/or maintain sleep, and hypersomnia, defined as excessive daytime sleepiness (EDS) and/or excessive sleep duration, are key symptoms in the diagnostic criteria of depression. A sizeable number of studies have demonstrated clear associations between insomnia and poorer depressive outcomes. These include greater depressive symptom severity, poorer treatment response and increased risk of suicidal ideations and attempts. Persistent insomnia complaints following remission of major depressive episodes (MDE) have also been found to be associated with greater risk of recurrence, poorer overall functioning and quality of life. Compared to insomnia, there is much less research on the role of hypersomnia in depressive illness.

Studies so far have suggested a prognostic significance. Hypersomnia in depressed subjects amongst a mix of mood disorders have been linked to greater treatment-resistance, depressive relapse, higher suicidal ideations and increased risk of suicide; while hypersomnia complaints amongst general populations have predicted the risk of incident depression. More recently, studies of depressed individuals amongst a mix of mood disorders had further found that the concurrence of insomnia and hypersomnia was associated with worse symptomatology compared to patients with insomnia or hypersomnia alone. These studies also found that the concurrence of insomnia and hypersomnia had greater associations with bipolar spectrum features, which builds on from previous findings suggesting that hypersomnia itself may be a clinical marker for undetected or subsequent diagnosis of bipolar II disorders in depressed patients.

Knowledge gaps in the understanding of hypersomnia in major depression

Despite its prognostic implications, there is currently a lack of studies investigating potential determinants or clinical correlates of hypersomnia in major depressive disorder (MDD). MDD is one of the commonest diagnoses encountered in the outpatient setting, and may be distinct in its determinants and outcomes compared to other mood disorders. Existing studies on hypersomnia in depression have predominantly included subjects from a mix of mood disorders; thus, a gap exists to extend the scope of understanding on hypersomnia amongst unipolar depression.

Due to the lack of standardized definitions, even amongst contemporary classifications, there is little clarity as to which aspect of hypersomnia - i.e. whether EDS or excessive sleep duration, or in combination - is related to poorer depressive outcomes. Moreover, little is known about what severity of "excessive" daytime sleepiness and sleep duration may be of clinical significance. Most studies of hypersomnia in mood disorders have used crude definitions, predominantly in form of single yes/no questions, to define hypersomnia. Despite the availability of validated questionnaires such as the Epworth Sleepiness Scale (ESS) that could help quantify EDS, or the use of sleep diaries that may help determine an individual's average sleep duration, limited studies of hypersomnia in MDD have employed these tools. The variability in definitions have also resulted in a large range of reported prevalence - between 8.9% to 78% of hypersomnia in MDD samples. In order to generate more clinically useful data, it may be helpful to "deconstruct" hypersomnia into EDS and prolonged sleep duration, to quantify them using validated or clinically-relevant measures, and further analyze their associations with potential determinants and depressive outcomes.

Theoretically, a myriad of factors can contribute to EDS or prolonged sleep duration. These include physical-health related factors, such as the use of sedative medications, the presence of medical illnesses and sleep-related breathing disorders; also sleep-related factors, such as the need for shift-work, the presence of insomnia or other sleep-behavioral disturbances, or the presence of circadian-disorders or particular chronotype preferences. Psychiatric factors, such as increased anxiety, somatic complaints and perceived fatigue levels, may also be related to EDS or prolonged sleep duration. So far, no studies have simultaneously examined this range of factors and their potential associations with hypersomnia complaints in MDD. Whether these factors mediate or act synergistically with hypersomnia to influence depressive outcomes remain to be elucidated.

A limitation that many hypersomnia studies have faced is the lack of objective measures used to corroborate subjective measures of EDS or sleep duration. The mean sleep latency test (MSLT) is currently regarded as the gold standard objective measure for EDS, while polysomnography (PSG) and wrist actigraphy has been useful in validating sleep diary data. However, the costs, expertise and time required to conduct these tests have limited their use. A study involving the use of both subjective and objective measures of EDS or sleep duration, in addition to a thorough analysis of the potential determinants and clinical correlates, may provide valuable information on the clinical profiles of hypersomnia patients and shed light on areas for further research and management.

Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Subjects will be successively recruited from August 2018 to August 2019 from the out-patient psychiatric clinics within the New Territories Eastern Cluster.
Condition Major Depressive Disorder
Intervention Other: No intervention involved
No intervention involved
Study Groups/Cohorts
  • MDD with hypersomnia
    Patient with a history of MDD and ESS >10
    Intervention: Other: No intervention involved
  • MDD without hypersomnia
    Patient with a history of MDD and ESS <=10
    Intervention: Other: No intervention involved
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: July 2, 2019)
350
Original Estimated Enrollment Same as current
Estimated Study Completion Date August 31, 2020
Estimated Primary Completion Date February 28, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • patients aged between 18-64 years old with a history of MDD

Exclusion Criteria:

  • patients with history of bipolar disorder, schizophrenic-spectrum disorder, substance abuse, alcohol dependence, dementia, patients with history of mental retardation and those unable to give consent.
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 64 Years   (Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Maxine Cheung, Dr. 852-57967576 cms044@ha.org.hk
Contact: YK Wing, Prof. 852-39197593 ykwing@cuhk.edu.hk
Listed Location Countries Hong Kong
Removed Location Countries  
 
Administrative Information
NCT Number NCT04006834
Other Study ID Numbers CREC2018.317
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Dr. Zhang Jihui, Chinese University of Hong Kong
Study Sponsor Chinese University of Hong Kong
Collaborators Not Provided
Investigators
Principal Investigator: Zhang JiHui, Dr CUHK
PRS Account Chinese University of Hong Kong
Verification Date September 2019